Quick Answer
Artiva Biotherapeutics, Inc. reported Total Revenue of $251.0 thousand for fiscal year 2024.
Artiva Biotherapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | — | $251.0K -99.3% |
$33.49M | — |
| Revenue (ASC 606) | — | — | $32.92M | — |
| Net Income | -$83.86M -28.3% |
-$65.37M -127.6% |
-$28.72M | — |
| Diluted EPS | -$3.43 +41.0% |
-$5.81 +83.8% |
-$35.78 | — |
| Total Assets | $130.94M -37.5% |
$209.58M +99.4% |
$105.11M | — |
| Cash and Equivalents | $26.70M -33.6% |
$40.23M -24.8% |
$53.50M | — |
| Stockholders Equity | $109.97M -41.1% |
$186.64M +215.2% |
-$162.01M -15.2% |
-$140.70M |
| R&D Expense | $69.54M +38.2% |
$50.33M +0.2% |
$50.25M | — |
| Operating Income | -$89.81M -33.5% |
-$67.28M -119.4% |
-$30.67M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2023 | $26.66M | — | +662.3% |
| Revenue (ASC 606) | September 30, 2023 | $26.66M | — | +662.3% |
| Net Income | September 30, 2025 | -$21.53M | -23.2% | -1.3% |
| Diluted EPS | September 30, 2025 | -$0.88 | +4.3% | -1.1% |
| Total Assets | September 30, 2025 | $148.86M | -34.0% | -12.1% |
| Cash and Equivalents | September 30, 2025 | $25.51M | -54.4% | -10.4% |
| Stockholders Equity | September 30, 2025 | $129.22M | -35.7% | -13.3% |
| R&D Expense | September 30, 2025 | $17.63M | +30.4% | -1.3% |
| Operating Income | September 30, 2025 | -$22.90M | -24.9% | -0.4% |
- Artiva Biotherapeutics, Inc. reported Total Revenue of $251.0 thousand for fiscal year 2024.
- Artiva Biotherapeutics, Inc. showed a decrease of -99.3% in Total Revenue compared to the prior fiscal year.
- Artiva Biotherapeutics, Inc. reported Revenue (ASC 606) of $32.92 million for fiscal year 2023.
- Artiva Biotherapeutics, Inc. reported Net Income of -$83.86 million for fiscal year 2025.
- Artiva Biotherapeutics, Inc. showed a decrease of -28.3% in Net Income compared to the prior fiscal year.
- Artiva Biotherapeutics, Inc. reported Diluted EPS of $3.43 per share (loss) for fiscal year 2025.
- Artiva Biotherapeutics, Inc. showed an increase of +41.0% in Diluted EPS compared to the prior fiscal year.
- Artiva Biotherapeutics, Inc. reported Total Assets of $130.94 million for fiscal year 2025.
- Artiva Biotherapeutics, Inc. showed a decrease of -37.5% in Total Assets compared to the prior fiscal year.
- Artiva Biotherapeutics, Inc. reported Cash and Equivalents of $26.70 million for fiscal year 2025.
- Artiva Biotherapeutics, Inc. showed a decrease of -33.6% in Cash and Equivalents compared to the prior fiscal year.
- Artiva Biotherapeutics, Inc. reported Stockholders Equity of $109.97 million for fiscal year 2025.
- Artiva Biotherapeutics, Inc. showed a decrease of -41.1% in Stockholders Equity compared to the prior fiscal year.
- Artiva Biotherapeutics, Inc. reported R&D Expense of $69.54 million for fiscal year 2025.
- Artiva Biotherapeutics, Inc. showed an increase of +38.2% in R&D Expense compared to the prior fiscal year.
- Artiva Biotherapeutics, Inc. reported Operating Income of -$89.81 million for fiscal year 2025.
- Artiva Biotherapeutics, Inc. showed a decrease of -33.5% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: